HCV treatment reduces liver cancer mortality risks

We know that identifying and treating HCV early with 8-12 weeks of direct acting anti-viral (DAA) medication can prevent the development of hepatocellular carcinoma (HCC), a very dangerous form of liver cancer. But did you know that treatment can also reduce the risk of death in patients who already have a history of HCC? Researchers at University of Texas Southwestern have shared findings from a new study that show how beneficial DAA treatment is — even in patients who have a history of cancer.

Read more here

Learn more about HCC through our one pager and on our Provider Resources page.

Article Categories: News